Novel Treatment Paradigms: Primary IgA Nephropathy
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driv...
Saved in:
| Main Authors: | Haresh Selvaskandan, Jonathan Barratt, Chee Kay Cheung |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024923016157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report
by: Shuang-xi Li, et al.
Published: (2025-05-01) -
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01) -
Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
by: Lingqiu Dong, et al.
Published: (2025-12-01) -
Clinical values of serum Gd-IgA1, complement factor H and complement regulatory proteins in IgA nephropathy
by: Zou Mei, et al.
Published: (2025-05-01) -
Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)